Correction: Amyvid makers call for CMS coverage of amyloid imaging

The article "Amyvid makers call for CMS coverage of amyloid imaging," has been revised.

The original text read:

Developers of the first FDA-approved imaging agent for the diagnosis of Alzheimer’s, Eli Lily and Company and Avid Pharmaceuticals, held a conference call May 16 for stakeholders and members of the media to discuss the Center for Medicare & Medicaid Service's (CMS) upcoming draft decision regarding coverage for Amyvid and other beta-amyloid type diagnostic agents.

The corrected version reads:

Developers of the first FDA-approved imaging agent for the detection of beta amyloid, Eli Lily and Company and Avid Pharmaceuticals, held a conference call May 16 for stakeholders and members of the media to discuss the Center for Medicare & Medicaid Service's (CMS) upcoming draft decision regarding coverage for Amyvid and similar biomarkers for imaging amyloid burden in the brain.

Molecular Imaging apologizes for the misrepresentation.